Cargando…

Olaparib Conjugates with Selenopheno[3,2-c]quinolinone Inhibit PARP1 and Reverse ABCB1-Related Multidrug Resistance

The restoration of the efficacy of antitumor medicines is a cornerstone in the combat with multidrug resistant (MDR) cancers. The overexpression of the ABCB1 transporter is a major obstacle to conventional doxorubicin therapy. The synergy of ABCB1 suppression and PARP1 activity inhibition that hampe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makrecka-Kuka, Marina, Vasiljeva, Jelena, Dimitrijevs, Pavels, Arsenyan, Pavel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783898/ https://www.ncbi.nlm.nih.gov/pubmed/36559065 http://dx.doi.org/10.3390/pharmaceutics14122571

Ejemplares similares

Fused isoselenazolium salts suppress breast cancer cell growth by dramatic increase in pyruvate-dependent mitochondrial ROS production
por: Makrecka-Kuka, Marina, et al.
Publicado: (2020)

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer()
por: Lombard, Alan P, et al.
Publicado: (2019)

Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
por: Voorneveld, Jim, et al.
Publicado: (2020)

Inhibition of CPT2 exacerbates cardiac dysfunction and inflammation in experimental endotoxaemia
por: Makrecka‐Kuka, Marina, et al.
Publicado: (2020)

Cytotoxicity of Amino‐BODIPY Modulated via Conjugation with 2‐Phenyl‐3‐Hydroxy‐4(1H)‐Quinolinones
por: Porubský, Martin, et al.
Publicado: (2021)

Recent Syntheses of 1,2,3,4-Tetrahydroquinolines, 2,3-Dihydro-4(1H)-quinolinones and 4(1H)-Quinolinones using Domino Reactions
por: Nammalwar, Baskar, et al.
Publicado: (2013)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019)

Pharmacological activation of PPARβ/δ preserves mitochondrial respiratory function in ischemia/reperfusion via stimulation of fatty acid oxidation-linked respiration and PGC-1α/NRF-1 signaling
por: Papatheodorou, Ioanna, et al.
Publicado: (2022)

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
por: Jiang, Ruixin, et al.
Publicado: (2022)

Novel 2-Hydroselenonicotinonitriles and Selenopheno[2, 3-b]pyridines: Efficient Synthesis, Molecular Docking-DFT Modeling, and Antimicrobial Assessment
por: Abdellattif, Magda H., et al.
Publicado: (2021)

Evaluation of Physicochemical Properties of Amphiphilic 1,4-Dihydropyridines and Preparation of Magnetoliposomes
por: Petrichenko, Oksana, et al.
Publicado: (2021)

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
por: Vaidyanathan, Aparajitha, et al.
Publicado: (2016)

Reversal of ABCB1-related multidrug resistance by ERK5-IN-1
por: Wang, Fang, et al.
Publicado: (2020)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
por: Osoegawa, Atsushi, et al.
Publicado: (2017)

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2017)

PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
por: Liu, Chuan, et al.
Publicado: (2020)

Structure activity relationships and the binding mode of quinolinone-pyrimidine hybrids as reversal agents of multidrug resistance mediated by P-gp
por: Laiolo, Jerónimo, et al.
Publicado: (2021)

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
por: de Haan, R., et al.
Publicado: (2019)

Microwave assisted one-pot access to pyrazolo quinolinone and tetrahydroisoxazolo quinolinone derivatives via T3P®-DMSO catalysed tandem oxidative–condensation reaction
por: Gowda, Darshini, et al.
Publicado: (2023)

Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib
por: Gilabert, Marine, et al.
Publicado: (2014)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
por: Park, Hye Jeong, et al.
Publicado: (2018)

PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation
por: Kageyama, Shun-ichiro, et al.
Publicado: (2020)

Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
por: Gross, Maya, et al.
Publicado: (2022)

Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter
por: Qiu, Jian-Ge, et al.
Publicado: (2015)

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
por: Ji, Ning, et al.
Publicado: (2019)

Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance
por: Huang, Bao-Yuan, et al.
Publicado: (2017)

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Feng, Weiguo, et al.
Publicado: (2020)

Acetylcholinesterase Inhibition of Diversely Functionalized Quinolinones for Alzheimer’s Disease Therapy
por: Bautista-Aguilera, Óscar M., et al.
Publicado: (2020)

Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib
por: Gravells, Polly, et al.
Publicado: (2018)

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas
por: Czyż, Małgorzata, et al.
Publicado: (2016)

Olaparib, a PARP-1 inhibitor, protects retinal cells from ocular hypertension-associated oxidative damage
por: Yang, Yuting, et al.
Publicado: (2022)

Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
por: Fanucci, Kristina, et al.
Publicado: (2023)

Rebamipide, an Amino Acid Analog of 2(1H)-Quinolinone, Inhibits the Formation of Human Osteoclasts
por: Nanke, Yuki, et al.
Publicado: (2016)

High-Resolution Respirometry for Simultaneous Measurement of Oxygen and Hydrogen Peroxide Fluxes in Permeabilized Cells, Tissue Homogenate and Isolated Mitochondria
por: Makrecka-Kuka, Marina, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a8raj7hb2s99gv0hcnatiamj4n